Protein kinase inhibitors

Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 1, 2018
Medicine, Clinical medicine, Cancer, Lung cancer, Tyrosine kinase receptors, Oncology, Biopsy, ROS1, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Protein kinase inhibitors, Circulating tumor cell

Biocept's circulating tumor cell (CTC)-based assay confirmed detection of a ROS1 gene translocation in a patient diagnosed with non-small cell lung cancer who had previously received chemotherapy and was progressing.

Key Points: 
  • Biocept's circulating tumor cell (CTC)-based assay confirmed detection of a ROS1 gene translocation in a patient diagnosed with non-small cell lung cancer who had previously received chemotherapy and was progressing.
  • The article, "ROS1 in Liquid Biopsies ," was published in the May 2018 issue of the Journal of Thoracic Oncology.
  • TheROS1gene is structurally similar to ALK, andROS1gene rearrangements are found in 12% of non-small cell lung cancer (NSCLC) cases.
  • Biocept's Target Selector liquid biopsy platform has the ability to identify ALK gene translocations in patients using a simple blood sample.

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018

Retrieved on: 
Monday, April 30, 2018
Chemistry, Organic chemistry, Clinical medicine, MEK inhibitor, Protein kinase inhibitors, Alcohols, Chloroarenes, South San Francisco, California, Binimetinib, Array BioPharma, Tucatinib, Larotrectinib

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions.

Key Points: 
  • Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions.
  • Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics).
  • For more information on Array, please go to www.arraybiopharma.com .

Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors

Retrieved on: 
Sunday, April 15, 2018
Lung cancer, Protein kinase inhibitors, Non-small-cell lung carcinoma

"We believe the safety, clinical activity and pharmacodynamic results from the dose escalation portion of the Phase 1 ARROW trial demonstrate compelling proof-of-concept for BLU-667.

Key Points: 
  • "We believe the safety, clinical activity and pharmacodynamic results from the dose escalation portion of the Phase 1 ARROW trial demonstrate compelling proof-of-concept for BLU-667.
  • Of these 53 patients, 27 patients (51 percent) had been previously treated with a multi-kinase inhibitor and 18 patients (34 percent) had been previously treated with an immunotherapy.
  • Patients and physicians interested in the ARROW trial can contact the Blueprint Medicines study team at [email protected] or 1-617-714-6707.
  • Blueprint Medicines is developing BLU-667, an investigational medicine, for the treatment of patients with RET-altered NSCLC, MTC and other solid tumors.